Heart attack patients get new drug to save more heart muscle

NCT ID NCT05292404

Recruiting now Disease control Sponsor: Shanghai Tong Ren Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving a PCSK9 inhibitor (alirocumab) soon after a heart attack can help save more heart muscle. About 160 adults having a specific type of heart attack will either get the drug or standard care. The main goal is to see if the drug improves heart muscle recovery, measured by MRI scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYOCARDIAL INFARCTION

Contacts and locations

Locations

Shanghai chest hospital
RECRUITING

Shanghai, Shanghai Municipality, 200050, China
Shanghai tongren hospital
RECRUITING

Shanghai, Shanghai Municipality, 200050, China
Songjiang hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, China
nineth people's hospital, School of Medicine, shanghai jiaotong university
RECRUITING

Shanghai, Shanghai Municipality, 200050, China
tenth people's hospital, tongji university, Shanghai
RECRUITING

Shanghai, Shanghai Municipality, 200050, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.